Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism-Reference-Cited by-同舟云学术

Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism

Published:2014-09-27 Issue:12 Volume:35 Page:12305-12315
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Zhao Jun-gang,Ren Kai-ming,Tang Jun

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-014-2543-3.pdf

Reference26 articles.

1. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, uft, s-1): a review. Oncologist. 2002;7:288–323.

2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.

3. DeBraud F, Munzone E, Nole F, De Pas T, Biffi R, Brienza S, et al. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol. 1998;21:279–83.

4. Zhang N, Yin Y, Xu SJ, Chen WS. 5-fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551–69.

5. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275–92.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing in vitro cytotoxic drug sensitivity in colon and pancreatic cancer using 2D and 3D cell models: Contrasting viability and growth inhibition in clinically relevant dose and repeated drug cycles;Cancer Medicine;2024-06

2. L-arginine combination with 5-fluorouracil inhibit hepatocellular carcinoma cells through suppressing iNOS/NO/AKT-mediated glycolysis;Frontiers in Pharmacology;2024-05-22

3. Comparingin vitrocytotoxic drug sensitivity in colon and pancreatic cancer using 2D and 3D cell models: contrasting viability and growth inhibition in clinically relevant dose and repeated drug cycles;2023-11-23

4. KRAS^G12C mutation‐induced TOPK overexpression contributes to tumour progression in non‐small cell lung cancer;Journal of Cellular and Molecular Medicine;2023-05-24

5. Synergistic Effects of the Combinational Use of Escitalopram Oxalate and 5-Fluorouracil on the Inhibition of Gastric Cancer SNU-1 Cells;International Journal of Molecular Sciences;2022-12-19